Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Capsugel has launched its enTRinsic drug delivery technology platform, which offers enteric protection without the requirement of functional coatings.
Subscribe to our email newsletter
The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract.
It allows oral delivery of several compounds, including vaccines, proteins and peptides, using pharmaceutically approved enteric polymers.
The technology is now available worldwide for customer projects after the completion of a lead-user customer-collaboration program, which was undertaken in 18 months.
The program included feasibility studies with new and existing pharmaceutical products.
Capsugel senior vice president of research and development Keith Hutchison said: "Our lead-user program confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale.
"We are now excited to move beyond the lead-user program and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs."
The enTRinsic technology further expands Capsugel’s range of modified and targeted release solutions, and the company’s biotherapeutic formulation offering.
Customers will be allowed to access the technology platform under a services agreement at the company’s locations in Ploërmel, France, and Bend, Oregon, US.